Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Island Pharmaceuticals Ltd has announced promising results from its ISLA-101 drug study, indicating effective blood concentration levels for dengue fever treatment from just a single dose. The data, critical for the upcoming Phase 2a trials, also reaffirms the drug’s safety and proper dosing levels. These findings mark significant progress in the drug’s development path, bolstering confidence as the company prepares for more extensive clinical testing.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.
